Bal Pharma Limited Files Compliance Certificate for Q4 FY26
Bal Pharma Limited filed a compliance certificate for the quarter ended March 31, 2026, confirming its Structured Digital Database (SDD) meets SEBI (PIT) Regulations. The database captures UPSI with an audit trail and is maintained internally.
This is a routine compliance filing and does not involve any new financial disclosures, strategic changes, or operational updates that would significantly impact the company's stock or business.
The announcement is a routine compliance filing related to insider trading regulations and the maintenance of a digital database. It does not contain any new financial information or significant business developments.
Bal Pharma Limited has submitted a compliance certificate for the quarter ended March 31, 2026, pertaining to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The company confirms the existence and proper functioning of its Structured Digital Database (SDD), which is used for capturing Unpublished Price Sensitive Information (UPSI). The certificate, signed by the Compliance Officer, Abdul Basith, on April 14, 2026, in Bangalore, states that the SDD is internally maintained, non-tamperable, has an audit trail, and can retain records for eight years. It also confirms that control exists over SDD access, and all UPSI disseminated in the previous quarter has been captured with its nature, date, and time. The company was required to capture two events during the quarter and successfully did so. No non-compliance issues were reported for the previous quarter.
What to do with a filing like this
Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.